INTRODUCTION
============

Tacrolimus (TAC) contributes to be the mainstay of immunosuppressive agents used for the management of multi-organ transplantation rejection and various autoimmune disorders. However, long-term use of TAC is often limited by its adverse side effects relation to diabetes mellitus (DM) and chronic nephropathy \[[@b1-kjim-2017-276]\]. Chronic TAC nephropathy has been reported in up to 20% of transplant recipients as well as in nontransplant settings \[[@b2-kjim-2017-276]\]. Glomerular injury caused by DM, inflammatory cell infiltration, and striped tubulointerstitial fibrosis (TIF) are characteristic features of this clinical dilemma, which is closely associated with renal dysfunction and proteinuria. Many molecular mechanisms account for chronic TAC nephropathy, and *in vivo* and *in vitro* studies have identified inflammatory mediators, transforming growth factor β1 (TGF-β1), oxidative stress, and apoptotic cell death as important factors \[[@b3-kjim-2017-276]-[@b5-kjim-2017-276]\].

Shen-Kang (SK) is a traditional Chinese herbal medicine that consists of 4 herbs components: rhubarb (*Rheum officinale* 16.7%), red sage (*Salvia miltiorrhiza* 16.7%), safflower (*Carthamus tinctorius* 16.6%), and astragalus (*Astragalus membranaceus* 50%). Because of the biological activities of these herbal components, the clinical use of SK injections has produced a significant reduction in proteinuria and an improvement of renal function in chronic kidney disease patients. Therefore, SK has been applied widely in the treatment of CKD patients in China over several decades. There is overwhelming evidence demonstrating that, through its antifibrotic and antioxidant potential, SK can effectively preserve renal proximal tubule epithelial cell (HK-2 cell) viability, inhibit high-glucose-induced proliferation of renal mesangial cells, and protect against renal lesions \[[@b6-kjim-2017-276]-[@b8-kjim-2017-276]\]. The renoprotective effects of SK have also been reported in 5/6 nephrectomy \[[@b6-kjim-2017-276],[@b9-kjim-2017-276]\], streptozotocin (STZ)-induced diabetic nephropathy (DN) \[[@b10-kjim-2017-276]\], and spontaneously hypertensive nephropathy \[[@b11-kjim-2017-276]\]. However, the beneficial effects of SK on TAC-induced nephropathy remain to be explored.

In this context, we aimed to investigate the renoprotective effect of SK in an experimental model of TAC-induced nephropathy.

METHODS
=======

Experimental design
-------------------

The protocol of the experimental study (CUMC-2016-0101-01) was approved by the animal care committee of the Catholic University of Korea. Male Sprague Dawley rats (Charles River Technology, Seoul, Korea) weighing 200 to 220 g were housed in individual cases (Nalge Co., Rochester, NY, USA) in a temperature- and light-controlled environment and allowed free access to a low-salt diet (0.05% sodium, Teklad Premier, Madison, WI, USA) and tap water. TAC (Prograf, Astellas Pharma, Ibaraki, Japan) was diluted in olive oil (Sigma, St Louis, MO, USA) to a final concentration of 1.5 mg/mL. The SK was kindly provided by the Xi'an ShiJi Shengkang Pharmaceutical Industry Co. Ltd. (Xi'an, China).

After acclimatization and a low-salt diet for 1 week, weight-matched rats were randomized into four subgroups and were treated daily for 4 weeks as follows: (1) subcutaneous injection with olive oil (1 mL/kg vehicle \[VH\]; n = 9); (2) simultaneous treatment with olive oil and SK (450 mg/kg intravenously, n = 9); (3) subcutaneous injection with TAC (1.5 mg/kg, n = 9); and (4) simultaneous treatment with TAC and SK (n = 9).

The SK injection was diluted in saline to a final concentration of 450 mg/mL and administered intravenously via tail vein at a dose of 450 mg/kg. The dosage and route of TAC and SK were based on previous studies \[[@b6-kjim-2017-276],[@b12-kjim-2017-276]\].

Basic parameters
----------------

Rats were pair-fed and their body weight (BW) was monitored daily. After the 4-week treatment period, animals were housed individually in metabolic cages (Tecniplast, Gazzada, Italy), and their water intake and urine volume were measured over 24 hours. On the following day, animals were anesthetized, and blood samples and tissue specimens were obtained for further analysis.

Measurement of urine albumin was performed using enzymatic colorimetric methods (Modular DPP system, Roche, Hamburg, Germany). Serum creatinine (Scr) and blood urea nitrogen (BUN) were measured using a quantitative enzymetic colorimetric method (Stanbio Laboratory, Boerne, TX, USA). Systolic blood pressure (SBP) was recorded in conscious rats by the tail-cuff method with plethysmography using a tail manometer-tachometer system (BP-2000, Visitech system, Apex, NC, USA). At least three readings were averaged for each rat. The whole-blood TAC level was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) \[[@b13-kjim-2017-276]\].

Blood glucose level
-------------------

Blood glucose level was measured with an intraperitoneal glucose tolerance test (IPGTT) at the end of the 4-week treatment period as described previously, and the area under the curve of glucose (AUCg) was calculated by trapezoidal estimation from the values obtained in the IPGTT \[[@b14-kjim-2017-276]\].

Histopathology
--------------

Kidney specimens were fixed in periodate-lysine-paraformaldehyde solution and embedded in wax. After dewaxing, 4-µm sections were processed and stained with periodic acid-Schiff (PAS) or Masson's trichrome and hematoxylin. Glomerular injury was assessed with mesangial matrix area. The mesangial matrix area was detected in PAS stained sections and semiquantified for each glomerular cross-section by a color image auto-analyzer (TDI Scope Eye Version 3.0 for Windows, Olympus, Tokyo, Japan). A finding of TIF was defined as a matrix-rich expansion of the interstitium with tubular dilatation, tubular atrophy, tubular cast formation, sloughing of tubular epithelial cells, or thickening of the tubular basement membrane. A minimum of 20 fields/sections was assessed using a color image auto-analyzer. Briefly, the image was captured, and the extent of TIF was quantified using the Polygon program by counting the percentage of areas injured per field of cortex under ×100 magnification. Histopathological analyses were performed in randomly selected cortical fields of sections by a pathologist blinded to the identity of the treatment groups \[[@b15-kjim-2017-276]\].

Immunohistochemistry
--------------------

After dewaxing, sections were incubated with 0.5% Triton X 100/PBS solution for 30 minutes and washed with phosphate buffered saline three times. Non-specific binding sites were blocked with normal horse serum diluted 1:10 in 0.3 % bovine serum albumin for 30 to 60 minutes, and then incubated for 2 hours at 4℃ in mouse antiserum against osteopontin (OPN, MPIIIB10, obtained from the Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) diluted in 1:1,000 in humid environment. After rinsing in Tris-buffered saline (TBS), sections were incubated in peroxidase-conjugated rabbit anti-mouse immunoglobulin G (Amersham Pharmacia Biotech, Piscataway, NJ, USA) for 30 minutes. For coloration, sections were incubated with a mixture of 0.05% 3,3'-diaminobenzidine containing 0.01% H~2~O~2~ at room temperature until a brown color was visible, washed with TBS, counterstained with hematoxylin and examined under light microscopy. The procedure of immunostaining for ectodermal dysplasia 1 (ED-1, AbD Seroec, Oxford, UK), Wilms tumor 1 (WT-1, Santa Cruz Biotechnology, Santa Cruz, CA, USA), angiotensin II (Ang II, Peninsula Labs, San Carlos, CA, USA), cysteinyl aspartate specific proteinase-3 (Caspase-3, Millipore, Billerica, MA, USA), manganese superoxide dismutase (MnSOD, Abcam, Cambridge, MA, USA), and 8-hydroxy-2'-deoxyguanosine (8-OHdG, JaICA, Shizuoka, Japan) was similar to that for OPN. Twenty different random glomeruli was evaluated to present the number of WT-1-positive cells per ×1,000 magnification view, and twenty different fields in each section at ×200 magnification were analyzed using a color image analyzer (TDI Scope Eye Version 3.0 for Windows) \[[@b3-kjim-2017-276]\]. Analysis of Ang II immunostaining was evaluated by counting the number of Ang II-positive juxtaglomerular afferent arterioles per total number of juxtaglomerular afferent arterioles available for examination, using a 20 objective; at least 50 glomeruli (not overlapping) were evaluated per section.

Immunoblotting analysis
-----------------------

Immunoblotting analyses were performed as previously described \[[@b16-kjim-2017-276]\]. Interleukin-17 (IL-17, Cell signaling Technology, Danvers, MA, USA), TGF-β1 (R&D Systems, Minneapolis, MN, USA), TGF-β inducible gene-h3 (βig-h3, Proteintech, Chicago, IL, USA), MnSOD (Abcam), Smad2/3 (Cell signaling Technology, Danvers, MA, USA), B-cell lymphoma-2 (Bcl-2, Santa Cruz Biotechnology), Bcl2-associated X (Bax, Delta Biolabs, Gilroy, CA, USA), and β-actin (Sigma) were detected with specific antibodies. Immunoblotting images were analyzed with an image analyzer (Quantity One, Bio-Rad Technical Service Department, Hercules, CA, USA). Optical densities were obtained using the VH group as 100% reference and normalized with β-actin.

Measurement of 8-OHdG level
---------------------------

Oxidative DNA damage was assessed by measuring the level of the DNA adduct 8-OHdG in serum and urine using a competitive enzyme-linked immunosorbent assay (Cell BIOLABS, San Diego, CA, USA).

*In situ* TdT-mediated dUTP-biotin nick end labeling assay
----------------------------------------------------------

Apoptosis in tissue sections was identified using the ApopTag *in situ* Apoptosis Detection Kit (Millipore). The number of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells was counted in 20 different fields in each section at ×200 magnification.

Statistical analysis
--------------------

The dates are expressed as mean ± standard error. Multiple comparisons among groups were fulfilled by oneway analysis of variance with the Bonferroni *post hoc* test (SPSS software version 19.0, IBM Co., Armonk, NY, USA). Statistical significance was accepted as *p* \< 0.05.

RESULTS
=======

Effect of SK on basic parameters
--------------------------------

[Table 1](#t1-kjim-2017-276){ref-type="table"} shows the effect of SK on basic parameters in the experimental groups. The mean BW of TAC-treated rats was significantly lower than that of VH-treated rats (54 ± 6 vs. 84 ± 6, *p* \< 0.01). SK treatment did not prevent loss of BW. TAC induced an increase in 24 hours water intake and urine volume compared with the VH group, whereas these parameters were unaffected by SK treatment. Urine albumin, Scr, and BUN were much higher in the TAC group compared with the VH group, but their levels were significantly decreased by concomitant administration of SK. Four-week TAC treatment led to an increase in blood TAC concentration to a level of 9.9 ± 1.4 ng/mL, whereas SK did not influence the level of TAC concentration (10.5 ± 1.7 ng/mL vs. 9.9 ± 1.4 ng/mL, *p* \> 0.05). There were no significant differences among groups for SBP.

Effect of SK on blood glucose in TAC-induced DM
-----------------------------------------------

Chronic TAC treatment is associated with induction of DM as manifested by increased IPGTT (578 ± 40 mg/dL/min vs. 357 ± 35 mg/dL/min, *p* \< 0.05) and AUCg (578 ± 40 mg/dL/min vs. 357 ± 35 mg/dL/min, *p* \< 0.05) when compared with the VH group. However, SK could not decrease the level of IPGTT (558 ± 38 mg/dL/min vs. TAC, *p* \> 0.05) or the AUCg (558 ± 38 mg/dL/min vs. TAC, *p* \> 0.05) ([Fig. 1](#f1-kjim-2017-276){ref-type="fig"}).

Effect of SK on TAC-induced histopathology in chronic TAC nephropathy
---------------------------------------------------------------------

Glomerular injury is a histological feature of chronic TAC nephropathy. TAC increased the fractional mesangial area (17.3% ± 2.4% vs. 5.8% ± 1.0%, *p* \< 0.05) and decreased the number of WT-1-positive cells (11.8 ± 0.8 vs. 22.8 ± 1.6, *p* \< 0.05). SK treatment significantly reversed the fractional mesangial area (12.1% ± 1.8% vs. TAC, *p* \< 0.05) and the number of WT-1-positive cells (16.7 ± 0.9 vs. TAC, *p* \< 0.05) ([Fig. 2](#f2-kjim-2017-276){ref-type="fig"}). TIF is a typical characteristic of chronic TAC nephropathy. TAC increased the TIF score (11.8% ± 2.5% vs. 0% ± 0%, *p* \< 0.05) compared with that of the VH group, whereas SK decreased the TIF score (4.6% ± 0.8% vs. TAC, *p* \< 0.05) compared with that of the TAC-treated group ([Fig. 3](#f3-kjim-2017-276){ref-type="fig"}).

Effect of SK on TAC-induced inflammation in chronic TAC nephropathy
-------------------------------------------------------------------

ED-1-positive cells were rarely detected in the kidneys of VH-treated rats (0.6% ± 0.1%). TAC treatment increased the number of ED-1-positve cells (23.2 ± 2.3 vs. VH, *p* \< 0.05). Concomitant administration of SK significantly decreased the number of ED-1-positive cells (15.1% ± 2.1% vs. TAC, *p* \< 0.05) ([Fig. 4](#f4-kjim-2017-276){ref-type="fig"}). Immunohistochemistry to assess OPN levels revealed a dramatic increase in OPN expression in the TAC-treated group compared with the VH group (8.9% ± 0.5% vs. 0.6% ± 0.1%, *p* \< 0.05). It is notable that the sites of strong OPN overexpression were in areas of inflammatory cell infiltration and severe TIF ([Fig. 5A](#f5-kjim-2017-276){ref-type="fig"}). SK dramatically suppressed OPN expression (3.6% ± 0.4% vs. TAC, *p* \< 0.05). Immunoblotting analysis of the kidney cortex revealed a dramatic increase in IL-17 protein expression in the TAC group compared with the VH group (150% ± 12% vs. 100% ± 10%, *p* \< 0.05), whereas SK significantly suppressed IL-17 expression (120% ± 11% vs. TAC, *p* \< 0.05) ([Fig. 5B](#f5-kjim-2017-276){ref-type="fig"}).

Effect of SK on TGF-β1/Smad2/3 signaling pathway and βig-h3 expression in chronic TAC nephropathy
-------------------------------------------------------------------------------------------------

The present study sought to compare the expression levels of the profibrotic cytokine TGF-β1/Smad2/3 signaling pathway and the extracellular matrix (ECM) component βig-h3 between treatment groups. The results of this study showed that TAC increased the levels of TGF-β1 (160% ± 11% vs. 102% ± 9%, *p* \< 0.05) and phosphorylation Smad2/3 protein expression (165% ± 20% vs. 100% ± 9%, *p* \< 0.05) when compared with the VH ([Fig. 6](#f6-kjim-2017-276){ref-type="fig"}), whereas SK inhibited TGF-β1 (104% ± 5% vs. TAC, *p* \< 0.05) and phosphorylation Smad2/3 protein (120% ± 16% vs. TAC, *p* \< 0.05) expression compared with TAC. As shown in [Fig. 6](#f6-kjim-2017-276){ref-type="fig"}, TAC treatment significantly increased βig-h3 expression compared with the VH group (230% ± 25% vs. 99% ± 10%, *p* \< 0.05), but this decreased significantly after SK co-treatment (150% ± 20% vs. TAC, *p* \< 0.05).

Effect of SK on Ang II in chronic TAC nephropathy
-------------------------------------------------

Intrarenal renin-angiotensin system (RAS) plays an important role in the pathogenesis of chronic TAC nephropathy \[[@b17-kjim-2017-276]\]. Immunohistochemistry showed that immunoreactivity of Ang II was increased in the TAC group compared with the VH, which was confined to the juxtaglomerular afferent arterioles ([Fig. 7](#f7-kjim-2017-276){ref-type="fig"}). However, there was no immunoreactivity of Ang II in glomerular cells and tubular cells. Concomitant administration of SK significantly suppressed intrarenal Ang II activity. Using semiquantitative analysis, we found that Ang II-positive glomeruli increased in the TAC group (62 ± 6 vs. 10 ± 2, *p* \< 0.05), and this was reversed in the TAC + SK group (31 ± 4 vs. TAC, *p* \< 0.05).

Effect of SK on oxidative stress in chronic TAC nephropathy
-----------------------------------------------------------

Levels of 8-OHdG, a marker of oxidative stress, were much higher in the TAC-treated group than in the VH group in serum (3.2 ± 0.06 ng/mL vs. 1.6 ± 0.05 ng/mL, *p* \< 0.05), urine (23 ± 14 ng/day vs. 9.7 ± 1.9 ng/day, *p* \< 0.05), and the kidney (15.6 ± 2.2%/mm^2^ vs. 5.3 ± 1.8%/mm^2^, *p* \< 0.05). SK considerably decreased 8-OHdG levels in serum (1.8 ± 0.03 ng/mL vs. TAC, *p* \< 0.05), urine (16.2 ± 1.7 ng/day vs. TAC, *p* \< 0.05), and the kidney (9.1 ± 1.8%/mm^2^ vs. TAC, *p* \< 0.05) compared with TAC ([Fig. 8](#f8-kjim-2017-276){ref-type="fig"}). In addition, we detected the expression of the antioxidant MnSOD in the kidneys by immunohistochemistry and immunoblotting. Immunohistochemistry revealed that most cortical structures, especially tubules, constitutively expressed MnSOD. In contrast, the expression and immunoreactivity of MnSOD were significantly suppressed in the tubules of the kidneys of TAC-treated rats ([Fig. 9A](#f9-kjim-2017-276){ref-type="fig"}). SK treatment preserved MnSOD expression. Immunoblotting consistently showed that MnSOD expression decreased in the kidneys of TAC-treated rats compared with those of VH rats by approximately 50% (52% ± 10% vs. 103% ± 8%, *p* \< 0.05), whereas this suppression was reversed by concomitant treatment with SK and remained at normal levels (109% ± 5% vs. TAC, *p* \< 0.05) ([Fig. 9B](#f9-kjim-2017-276){ref-type="fig"}).

Effect of SK on apoptotic cell death in chronic TAC nephropathy
---------------------------------------------------------------

In this study, we examined renal cell apoptosis and the expression of related genes in the kidney, because this process plays a critical role in chronic TAC-induced nephropathy. By using a TUNEL assay, we found that TAC significantly increased the number of TUNEL-positive cells compared with the VH (10.2 ± 2.0 cell/mm^2^ vs. 0.6 ± 0.1 cell/mm^2^, *p* \< 0.05). Consistent with previous studies \[[@b18-kjim-2017-276],[@b19-kjim-2017-276]\], most TUNEL-positive cells were localized to tubules and interstitium, where severe TIF and tubular atrophy had developed ([Fig. 10A](#f10-kjim-2017-276){ref-type="fig"}). The concomitant administration of SK to rats markedly reduced the number of TUNEL-positive cells compared with the result seen in the TAC group (4.6 ± 1.8 cell/mm^2^ vs. TAC, *p* \< 0.05). At a molecular level, SK treatment modulated the expression of apoptosis-related genes in favor of cell survival, which included an increase in the Bcl-2/Bax ratio (103% ± 2% vs. 65% ± 6%, *p* \< 0.05) and a decrease in the number of caspase-3-positive cells (3.6% ± 0.4% vs. 8.1% ± 0.4%, *p* \< 0.05) ([Figs. 10B](#f10-kjim-2017-276){ref-type="fig"} and [11](#f11-kjim-2017-276){ref-type="fig"}).

DISCUSSION
==========

Chronic TAC nephropathy contributes to the risk of end-stage renal disease requiring maintenance dialysis, and increases over time in renal and nonrenal transplant recipients. Thus, reducing this complication represents an important therapeutic strategy. This study clearly showed that SK treatment prevented glomerular and tubulointerstitial injury in the kidneys of TAC-treated rats, and this histological improvement was accompanied by recovery from renal dysfunction and proteinuria. Our results expand the known roles of the traditional Chinese herbal medicine SK to the prevention of TAC-induced renal injury.

Inflammation is critical in the development of chronic TAC nephropathy, which precedes TIF, and several proinflammatory mediators are involved in this process. OPN is a potent chemotactic and adhesive factor for macrophages, and increasing evidence has confirmed that the upregulation of tubular OPN expression is strongly associated with macrophage infiltration subsequent to tubulointerstitial injury in chronic TAC nephropathy \[[@b20-kjim-2017-276]\]. This concept is supported by data on OPN-gene knockout mice and antisense-treated or anti-OPN antibody-treated animals that demonstrated a significant reduction in macrophage influx and renal architecture impairment \[[@b21-kjim-2017-276],[@b22-kjim-2017-276]\]. We have recently revealed that overexpression of OPN plays a pathological role in TAC-induced renal injury \[[@b3-kjim-2017-276],[@b5-kjim-2017-276]\]. Recently, increasing evidence suggests that IL-17 triggers a renal inflammatory response in the kidneys of diabetes \[[@b23-kjim-2017-276],[@b24-kjim-2017-276]\]. In this study, we anticipated that SK would attenuate tubulointerstitial inflammation caused by TAC because SK inhibits inflammatory mediators (C-reactive protein, tumor necrosis factor α, and IL-6) in a rat model of hypertensive renal damage and decreases renal interstitial CD68+ cell infiltration in STZ-induced diabetic rats fed a high-sugar and high-fat diet \[[@b10-kjim-2017-276],[@b11-kjim-2017-276]\]. Our results showed that SK treatment downregulated renal OPN and IL-17 expression, leading to a reduction in the number of ED-1-positive cells. This finding implies that SK possesses an anti-inflammatory property in chronic TAC nephropathy.

Unlike cyclosporine nephropathy, chronic TAC nephropathy is manifested by typical histological features including not only striped TIF but also glomerular injury. As a result, chronic TAC nephropathy involves both renal dysfunction and proteinuria \[[@b3-kjim-2017-276]\]. It is well known that TGF-β1 plays a pivotal role in renal scarring in a wide range of kidney diseases probably by its action on ECM synthesis and degradation \[[@b25-kjim-2017-276]-[@b27-kjim-2017-276]\]. It has been confirmed by *in vivo* and *in vitro* studies that TAC induces TGF-β1 expression either directly or indirectly. TAC may act directly to stimulate TGF-β1 secretion in human renal proximal tubule epithelial cells \[[@b28-kjim-2017-276]\]. However, TAC may also induce TGF-β1 indirectly through activation of the RAS \[[@b3-kjim-2017-276],[@b29-kjim-2017-276]\]. In this study, we found that the upregulated expression of TGF-β1/p-Smad2/3 and the ECM component βig-h3 in the kidneys of the TAC-treated rats was significantly decreased after SK treatment, and this was accompanied by improved renal dysfunction and urine albumin excretion. Moreover, SK treatment significantly decreased the number of Ang II-positive glomeruli. In addition to TIF, SK decreased the glomerular mesangial fractional area, increased the number of podocytes, and preserved foot process structure. These findings are consistent with our previous studies and suggest that SK is effective in protecting against TAC-induced renal injury.

Many mechanisms may account for the antiinflammatory and antifibrotic effects of SK in chronic TAC nephropathy, and the involvement of oxidative stress and apoptotic cell death should be considered. Short- and long-term TAC treatment is associated with afferent arteriolopathy-related hypoxia, which ultimately results in oxidative stress-induced tubulointerstitial inflammation and renal injury \[[@b3-kjim-2017-276],[@b5-kjim-2017-276]\]. SK elicits antifibrosis and antioxidation in a CKD model established by 5/6 nephrectomy and puromycin aminonucleoside-induced nephrosis \[[@b8-kjim-2017-276],[@b30-kjim-2017-276]\]. In addition, apoptotic cell death plays an important role in TAC-induced renal damage because TAC induces renal cell apoptosis *in vivo* and *in vitro* \[[@b18-kjim-2017-276],[@b31-kjim-2017-276],[@b32-kjim-2017-276]\]. Liu et al. \[[@b6-kjim-2017-276]\] reported that SK treatment significantly prevented renal proximal tubule epithelial cells (HK-2 cells) from hydrogen peroxide-induced apoptosis. The results of this study showed that SK decreased 8-OHdG levels in serum, urine, and the kidney, and increased antioxidant MnSOD production. Moreover, SK reduced the number of TUNEL-positive cells and modulated apoptosis-related genes (caspase-3 and the Bcl-2/Bax ratio) that favor cell survival. Indeed, the protective effect of SK on TAC-treated kidneys in this study may be, in part, related to its actions on oxidative stress and apoptosis.

In clinical practice, SK injection has been routinely applied to treat stage 1 to stage 3 CKD patients in China without adverse side effects. However, the molecular mechanism underlying the renoprotective effect of SK is rarely explored. In recent reports, SK has been found to protect against renal injury in animal models of 5/6 nephrectomy and STZ-induced DN through its antioxidant and antifibrotic potential \[[@b9-kjim-2017-276],[@b10-kjim-2017-276]\]. In this study, we showed antiinflammatory and antiapoptotic effects of SK in TAC-induced renal injury. Therefore, SK elicits protective effects in the kidney owing to its antioxidant and antiapoptotic properties. Of note, SK improved renal dysfunction and proteinuria, but it failed to influence blood glucose level as measured by IPGTT and AUCg, which was increased in TAC-treated rats. This observation suggests that, although SK did not affect DM caused by TAC, it was still effective in preventing chronic TAC-induced nephropathy.

In summary, this study demonstrates that SK offers antiinflammatory and antifibrotic effects in a rat model of chronic TAC nephropathy. Suppression of oxidative stress and apoptotic cell death may be one of the mechanisms underlying the renoprotective properties of SK. Our findings provide a potential rationale for the clinical use of SK in reducing chronic TAC-induced nephropathy.

KEY MESSAGE
===========

1\. Shen-Kang protects against glomerular injury by decreasing fractional mesangial area and preserving podocyte number.

2\. Shen-Kang protects against tubulointerstitial inf lammation and fibrosis by suppressing osteopontin, interleukin 17, transforming growth factor β1/Smad2/3, and βig-h3 (inducible gene-h3) expression.

3\. Shen-Kang inhibits renal cell apoptosis through decreasing caspase-3 expression and upregulating the B-cell lymphoma-2/Bcl2-associated X (Bcl-2/Bax) ratio.

4\. Shen-Kang suppresses oxidative stress through decreasing 8-hydroxy-2'-deoxyguanosine levels and restoring manganese superoxide dismutase production.
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![Blood glucose levels between treatment groups. (A) Intraperitoneal glucose tolerance test and (B) area under the curve of glucose (AUCg). VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f1){#f1-kjim-2017-276}

![Representative photomicrographs of glomerular injury and semiquantitative analysis. (A) Periodic acid-Schiff staining (×400), (B) semiquantitative analysis of the fractional mesangial area, (C) immunohistochemistry for Wilms tumor 1 (WT-1) (×400), and (D) semiquantitative analysis of WT-1-positive glomerulus. VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f2){#f2-kjim-2017-276}

![Representative photomicrographs of tubulointerstitial fibrosis (TIF) and semiquantitative analysis. (A) Trichrome staining (×40) and (B) semiquantitative analysis of TIF. VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f3){#f3-kjim-2017-276}

![(A) Representative photomicrographs of immunohistochemistry for ectodermal dysplasia 1 (ED-1) (×200) and (B) semiquantitative analysis. VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f4){#f4-kjim-2017-276}

![Representative photomicrographs of (A) immunohistochemistry for osteopontin (OPN) (×200) and (B) immunoblotting of interleukin 17 (IL-17). VH, vehicle; SK, ShenKang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, b ^a^ *p* \< 0.05 vs. TAC.](kjim-2017-276f5){#f5-kjim-2017-276}

![(A) Immunoblotting of (B) transforming growth factor β1 (TGF-β1), (C) Smad2/3, and (D) inducible gene-h3 (βig-h3) and quantitative analysis. VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f6){#f6-kjim-2017-276}

![Representative photomicrographs of immunohistochemistry for (A) angiotensin II (Ang II) (×400) and (B) semiquantitative analysis (arrow). VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f7){#f7-kjim-2017-276}

![8-Hydroxy-2'-deoxyguanosine (8-OhdG) levels in (A) serum, (B) urine, and (C, D) the kidney (immunohistochemical staining, ×200). VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f8){#f8-kjim-2017-276}

![(A) Immunohistochemistry and (B) immunoblotting of manganese superoxide dismutase (MnSOD) (immunohistochemical staining, ×200). VH, vehicle; SK, ShenKang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f9){#f9-kjim-2017-276}

![Representative photomicrographs of (A) terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay and (B) immunohistochemistry for caspase-3 (×200). VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f10){#f10-kjim-2017-276}

![(A) Immunoblotting of B-cell lymphoma-2 (Bcl-2) and Bcl2-associated X (Bax) and (B) quantitative analysis of the Bcl-2/Bax ratio. VH, vehicle; SK, Shen-Kang; TAC, tacrolimus. ^a^ *p* \< 0.05 vs. VH, ^b^ *p* \< 0.05 vs. TAC.](kjim-2017-276f11){#f11-kjim-2017-276}

###### 

Effect of SK on basic parameters

  Variable         VH            VH + SK       TAC                                                          TAC + SK
  ---------------- ------------- ------------- ------------------------------------------------------------ ------------------------------------------------------------
  ∆BW, g           84 ± 6        81 ± 11       54 ± 6^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^        57 ± 3^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^
  UV, mL/day       9.1 ± 2.3     10.1 ± 1.6    26.0 ± 3.1^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^    23.2 ± 3.5^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^
  WI, mL/day       15 ± 4        17 ± 5        30 ± 3^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^        27 ± 5^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^
  UA, mg/day       9.0 ± 2.3     8.9 ± 2.1     29.5 ± 2.8^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^    18.1 ± 3.5^[b](#tfn2-kjim-2017-276){ref-type="table-fn"}^
  Scr, mg/dL       0.35 ± 0.07   0.27 ± 0.02   0.64 ± 0.06^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^   0.51 ± 0.05^[b](#tfn2-kjim-2017-276){ref-type="table-fn"}^
  BUN, mg/dL       14 ± 3        13 ± 1        47 ± 6^[a](#tfn1-kjim-2017-276){ref-type="table-fn"}^        33 ± 3^[b](#tfn2-kjim-2017-276){ref-type="table-fn"}^
  SBP, mmHg        118 ± 10      120 ± 9       120 ± 12                                                     119 ± 11
  TAC con, ng/mL   \-            \-            9.9 ± 1.4                                                    10.5 ± 1.7

Values are presented as mean ± SD.

SK, Shen-Kang; VH, vehicle; TAC, tacrolimus; ΔBW, body weight gain; UV, urine volume; WI, water intake; UA, urine albumin; Scr, serum creatinine; BUN, blood urea nitrogen; SBP, systolic blood pressure.

*p* \< 0.05 vs. VH.

*p* \< 0.05 vs. TAC.
